E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare overall survival between treatment with primary cytoreductive surgery and HIPEC (intervention), and treatment with primary cytoreductive surgery without HIPEC (standard), in patients with FIGO stage III ovarian cancer who are treated with primary cytoreductive surgery resulting in no residual disease, or residual disease up to 2.5 mm. |
|
E.2.2 | Secondary objectives of the trial |
-To compare recurrence-free survival between both treatment arms -To compare time to first subsequent anticancer treatment after first recurrent disease (TFST) Toxicity and morbidity of both treatment arms are reported using the Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0 for all events, and using the Clavien-Dindo method for surgery-related events. Exploratory objectives -To compare time to second subsequent anticancer treatment after recurrence (TSST) -To evaluate the quality of life of the treatment arm compared to the standard arm , using the EORTC QLQ-CR30, QLQ-OV28 and QLQ-CR29 questionnaires. -To assess genetic profiles predictive of tumor response in patients with stage III ovarian cancer undergoing primary CRS with or without HIPEC. -To assess an economic- and cost evaluation of the procedure using the EQ-5D-5L questionnaire.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Signed and written informed consent 2.Age ≥18 3.Histological proven FIGO stage III primary epithelial ovarian, fallopian tube, or extra-ovarian cancer, treated with primary complete cytoreduction, or primary cytoreduction with no more than 2.5 mm residual disease a.in case of extra-abdominal enlarged lymph nodes, representative cytology/histology or FDG-PET scan must be negative; b.resectable, local bowel involvement or umbilical lesions are allowed; c.in case no histological proof is available before surgery, patients can be randomized during surgery based on histological proof on intraoperative frozen section material 4.Fit for major surgery, WHO performance status 0-2 5.Adequate bone marrow function (hemoglobin level >5.5 mmol/L; neutrophils >1.5 x 109/L; platelets >100 x 109 /L) 6.Adequate hepatic function (ALT, AST and bilirubin <2.5 times upper limit of normal) a.in case of Gilbert’s disease: unconjugated bilirubin <5 times upper limit of normal 7.Adequate renal function (creatinine clearance using Cockcroft –Gault formula ≥ 60 ml/min2) 8.Baseline health-outcome questionnaire should be completed before randomization 9.To be able to understand the patient information and questionnaires.
|
|
E.4 | Principal exclusion criteria |
1.History of previous malignancy treated with chemotherapy 2.History of previous malignancy within five years prior to inclusion, with the exception of carcinoma in situ of the cervix, radically excised basal cell or squamous cell cancer of the skin or synchronal endometrial carcinoma FIGO IA G1/2 3.If complete primary cytoreduction is not feasible, for the following reasons: a.diffuse deep infiltration of the root of small bowel mesentery, or; b.diffuse carcinomatosis of the small bowel that requires resection that leads to short bowel syndrome (remaining bowel <1.5 meter), or; c.diffuse involvement/deep infiltration of stomach/duodenum, or; d.diffuse involvement/deep infiltration of head or middle part of pancreas, or; e.Involvement of truncus coeliacus , hepatic arteries or left gastric artery, or; f.Non-resectable enlarged (larger than 10 mm short axis) lymph nodes 4.In case of a known psychiatric disorder, substance abuse disorder, or high suspicion of a mental disorder that could interfere with cooperation or compliance with the requirements of the trial 5.When opting for fertility sparing surgery, or when breastfeeding 6.In case of a known history of Human Immunodeficiency Virus (HIV, or HIV 1/2 antibodies) 7.In case of known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative]) 8.Patients who received prior treatment for the current malignancy.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.5.2 | Secondary end point(s) |
- Recurrence-free survival - The time to first subsequent anticancer treatment after first recurrent disease (TFST) - The toxicity and morbidity of both treatment arms -Time to second subsequent anticancer treatment after recurrence (TSST) -The health-related quality of life of both treatment arms, scored using the EORTC QLQ-CR30, QLQ-OV28 and QLQ-CR29 questionnaires -Economic- and cost effectiveness of the procedure, calculated with health state utilities assessed in the EQ-5D-5L questionnaire. -Predictive value of different biomarkers on tumor response.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 11 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |